Liquidia reports Q1 EPS 52c, consensus 41c

Reports Q1 revenue $129.9M, consensus $119.4M. Cash and cash equivalents totaled $222.8M as of March 31, 2026, vs. $190.7M as of December 31, 2025. CEO Roger Jeffs said: “In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of YUTREPIA and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent.”